How India Exports Procarbazine to the World

Procarbazine, an antineoplastic agent, has been approved in the United States for the treatment of Hodgkin's lymphoma. According to the FDA's Orange Book, there are multiple approved Abbreviated New Drug Applications (ANDAs) for procarbazine hydrochloride capsules, indicating the presence of generic versions in the market. The most recent ANDA approval was granted in March 2025. As of March 2026, there are no active FDA import alerts specifically targeting procarbazine or its manufacturers, suggesting compliance with FDA regulations among current suppliers.

Given the presence of 84 active Indian exporters and 318 shipment records from 2022 to 2026, it is evident that Indian manufacturers play a significant role in supplying procarbazine to the U.S. market. The average Free on Board (FOB) unit price of $102.88 underscores the competitive pricing offered by Indian exporters. This robust participation aligns with the FDA's regulatory framework, which facilitates the entry of generic drugs through the ANDA pathway, provided they meet stringent quality and safety standards.

In the European Union, procarbazine is subject to marketing authorization requirements overseen by the European Medicines Agency (EMA). Manufacturers must obtain approval to market procarbazine within EU member states, ensuring compliance with the EU's Good Manufacturing Practice (GMP) standards. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates the authorization and monitoring of medicinal products, including procarbazine. Compliance with these regulatory bodies ensures that procarbazine meets the necessary safety, efficacy, and quality standards for distribution within these regions.

Procarbazine is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in treating Hodgkin's lymphoma. The drug is recognized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions. However, as of March 2026, procarbazine has not been prequalified by the WHO Prequalification Programme, which primarily focuses on medicines for high-burden diseases such as HIV/AIDS, malaria, and tuberculosis.

In India, procarbazine is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for procarbazine, allowing market-driven pricing. For export purposes, Indian manufacturers are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

The primary patents for procarbazine have expired, leading to the availability of generic versions in various markets. This expiration has fostered increased competition among manufacturers, including the 84 active Indian exporters, thereby contributing to more affordable treatment options for patients globally.

In October 2025, the FDA updated its import alerts to reinforce that all unauthorized e-cigarettes may be detained without physical examination. While this action does not directly impact procarbazine, it reflects the FDA's ongoing efforts to regulate imported products rigorously. Additionally, in January 2025, the FDA announced the update of two import alerts, 98-07 and 98-06, to provide clearer instructions to FDA staff and the trade community regarding unauthorized e-cigarette products. These updates aim to prevent unauthorized products from entering the U.S. market, ensuring compliance with FDA regulations.

Furthermore, in March 2025, the FDA approved a new generic version of procarbazine hydrochloride capsules, expanding treatment options for patients with Hodgkin's lymphoma. This approval underscores the FDA's commitment to facilitating access to essential medications through the approval of generic drugs.

Procarbazine, an antineoplastic agent, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) imported from China. This dependency is part of a broader trend where approximately 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India, as reported by the U.S. Pharmacopeia in November 2025.

The reliance on Chinese KSMs introduces significant vulnerabilities. For instance, in September 2020, China increased prices of key drug materials by 10-20%, impacting the cost structures of Indian pharmaceutical manufacturers. Such price fluctuations and potential supply disruptions underscore the risks associated with this dependency.

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters of Procarbazine account for 54.4% of total exports, with SUNMOON CHEMICALS PRIVATE LIMITED alone contributing 25.8%. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could significantly impact global supply chains.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at reducing import dependence on critical pharmaceutical ingredients. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, marking a step towards self-reliance. However, the effectiveness of these initiatives in diversifying Procarbazine's supply base remains to be seen.

Recent geopolitical events have further strained the pharmaceutical supply chain. The Iran war, which began in late February 2026, led to the effective closure of the Strait of Hormuz, a critical maritime chokepoint. This disruption halted oil tanker movements and affected the distribution of pharmaceuticals from India, causing significant delays and increased costs. Additionally, tensions in the Red Sea and the Suez Canal have forced shipping companies to reroute vessels around Africa's Cape of Good Hope, adding further delays and expenses.

While there have been no specific FDA or EMA shortage alerts for Procarbazine as of March 2026, the cumulative impact of these disruptions poses a tangible risk to its global availability.

• Diversify KSM Sources: Encourage the development of alternative KSM suppliers in regions outside of China to reduce dependency and enhance supply chain resilience.

• Strengthen Domestic Production: Accelerate the implementation of the PLI scheme to boost domestic manufacturing of critical APIs and KSMs, thereby decreasing reliance on imports.

• Enhance Supplier Due Diligence: Conduct comprehensive assessments of supplier stability, including financial health and geopolitical exposure, to identify and mitigate potential risks.

• Develop Contingency Plans: Establish robust contingency strategies, such as maintaining strategic stockpiles and identifying alternative logistics routes, to address potential supply chain disruptions.

• Monitor Geopolitical Developments: Implement a proactive monitoring system for geopolitical events that could impact supply chains, enabling timely responses to emerging threats.

RISK_LEVEL: MEDIUM